entertainment -WSS

entertainment

author：hotspot 2025-08-23 22:01:29 - browse：41

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： ASCO: Palliative care found as helpful given virtually as in person

WSS

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Intellia reports positive results for its CRISPR

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Public health communication lessons from Covid

An outrageous hospital charge: I paid $710 for an hour of babysitting

leisure time

entertainment

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

BMI, flaws aside, is found to be useful estimate of body fat in youth

United colonoscopy coverage change 'may cost lives,' doctors say

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Jerome Adams on the need for new antivirals for Covid

Innovation in antibiotics is ailing. 'Brain drain' may kill it

After affirmative action ruling, medical educators look to 'holistic review'

CDC: Cases of alpha

entertainment

With trial win, GSK could get blood cancer drug back on market

CDC: Cases of alpha

At ASCO, AstraZeneca reports strong data for breast cancer drug

Behind warning on Apellis’s eye drug lies a conflict of interest

Behind warning on Apellis’s eye drug lies a conflict of interest

VC firm RA Capital starts a new synthetic biology incubator

explore

entertainment

explore

entertainment